| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash and cash equivalents | $1.0M-83.8% | $6.3M+310.1% | $1.5M-81.3% | $8.2M |
| Accounts receivable, net | $595K+38.4% | $430K+46.2% | $294K | — |
| Inventories, net | $635K-18.3% | $778K-20.7% | $980K | — |
| Research and development tax incentive receivable | $734K+39.8% | $525K+5.3% | $499K+41.3% | $353K |
| Assets held for sale | $328K | — | — | — |
| Other current assets | $827K+66.2% | $498K-10.0% | $553K-26.0% | $747K |
| Total current assets | $4.1M-51.5% | $8.5M+120.9% | $3.9M-64.5% | $10.9M |
| Property and equipment, net | $251K-55.6% | $566K-18.0% | $690K+76.3% | $391K |
| Operating lease right-of-use assets | $70K-77.3% | $307K-43.9% | $546K | — |
| Intangibles, net | $3.8M-13.3% | $4.4M-16.8% | $5.3M | — |
| Total assets | $8.2M-40.1% | $13.8M+33.1% | $10.4M-16.2% | $12.4M |
| Accounts payable and accrued expenses | $4.5M+166.0% | $1.7M-34.7% | $2.6M+60.6% | $1.6M |
| Current portion of operating lease liabilities | $85K-69.2% | $275K+23.0% | $223K | — |
| Deferred grant income | $2.5M | — | $2.3M-17.6% | $2.8M |
| Current employee benefit liabilities | $535K+14.0% | $469K+30.8% | $359K+78.3% | $201K |
| Notes payable | $197K-61.7% | $515K+45.9% | $353K | — |
| Total current liabilities | $5.4M-1.8% | $5.5M-7.4% | $5.9M+26.2% | $4.7M |
| Employee benefit liabilities, less current portion | $85K+33.5% | $64K+155.5% | $25K-50.8% | $51K |
| Operating lease liabilities, less current portion | $81K | — | $356K | — |
| Total liabilities | $5.4M-2.9% | $5.6M-16.1% | $6.7M+14.8% | $5.8M |
| Common stock, $0.01 par value, 100,000,000 shares authorized, 7,323,377 and 7,323,261 shares issued and outstanding, as of June 30, 2025, respectively; 3,456,116 and 3,456,000 shares issued and outstanding, as of June 30, 2024 respectively | $73K+111.9% | $35K+1679.5% | $2K-73.9% | $7K |
| Treasury stock, at cost, 116 shares as of June 30, 2025 and 2024 | -$1+0.0% | -$1+0.0% | -$1 | — |
| Additional paid-in capital | $65.8M+7.9% | $61.0M+32.0% | $46.2M+19.7% | $38.6M |
| Accumulated deficit | -$62.5M-20.3% | -$52.0M-24.3% | -$41.8M-34.1% | -$31.2M |
| Accumulated other comprehensive loss | -$328K+54.0% | -$713K-23.8% | -$575K+27.0% | -$788K |
| Total consolidated Intelligent Bio Solutions Inc. equity | $3.0M-64.0% | $8.3M+119.3% | $3.8M-42.7% | $6.6M |
| Non-controlling interest | -$182K-24.7% | -$146K-30.5% | -$112K-41.5% | -$79K |
| Total shareholders’ equity | $2.8M-65.6% | $8.2M+121.9% | $3.7M-43.7% | $6.5M |
| TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | $8.2M-40.1% | $13.8M+33.1% | $10.4M-16.2% | $12.4M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.